CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection : A Collaborative Analysis of 20 European Cohort Studies
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com..
BACKGROUND: A persistently low CD4/CD8 ratio has been reported to inversely correlate with the risk of non-AIDS defining cancer in people living with human immunodeficiency virus (HIV; PLWH) efficiently treated by combination antiretroviral therapy (cART). We evaluated the impact of the CD4/CD8 ratio on the risk of Kaposi sarcoma (KS) or non-Hodgkin lymphoma (NHL), still among the most frequent cancers in treated PLWH.
METHODS: PLWH from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) were included if they achieved virological control (viral load ≤ 500 copies/mL) within 9 months following cART and without previous KS/LNH diagnosis. Cox models were used to identify factors associated with KS or NHL risk, in all participants and those with CD4 ≥ 500/mm3 at virological control. We analyzed the CD4/CD8 ratio, CD4 count and CD8 count as time-dependent variables, using spline transformations.
RESULTS: We included 56 708 PLWH, enrolled between 2000 and 2014. At virological control, the median (interquartile range [IQR]) CD4 count, CD8 count, and CD4/CD8 ratio were 414 (296-552)/mm3, 936 (670-1304)/mm3, and 0.43 (0.28-0.65), respectively. Overall, 221 KS and 187 NHL were diagnosed 9 (2-37) and 18 (7-42) months after virological control. Low CD4/CD8 ratios were associated with KS risk (hazard ratio [HR] = 2.02 [95% confidence interval {CI } = 1.23-3.31]) when comparing CD4/CD8 = 0.3 to CD4/CD8 = 1) but not with NHL risk. High CD8 counts were associated with higher NHL risk (HR = 3.14 [95% CI = 1.58-6.22]) when comparing CD8 = 3000/mm3 to CD8 = 1000/mm3). Similar results with increased associations were found in PLWH with CD4 ≥ 500/mm3 at virological control (HR = 3.27 [95% CI = 1.60-6.56] for KS; HR = 5.28 [95% CI = 2.17-12.83] for NHL).
CONCLUSIONS: Low CD4/CD8 ratios and high CD8 counts despite effective cART were associated with increased KS/NHL risks respectively, especially when CD4 ≥ 500/mm3.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 73(2021), 1 vom: 01. Juli, Seite 50-59 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
CD4/CD8 ratio |
|---|
| Anmerkungen: |
Date Completed 22.09.2021 Date Revised 23.03.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciaa1137 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329149547 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329149547 | ||
| 003 | DE-627 | ||
| 005 | 20231225204502.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaa1137 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1097.xml |
| 035 | |a (DE-627)NLM329149547 | ||
| 035 | |a (NLM)34370842 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Caby, Fabienne |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection |b A Collaborative Analysis of 20 European Cohort Studies |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.09.2021 | ||
| 500 | |a Date Revised 23.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: A persistently low CD4/CD8 ratio has been reported to inversely correlate with the risk of non-AIDS defining cancer in people living with human immunodeficiency virus (HIV; PLWH) efficiently treated by combination antiretroviral therapy (cART). We evaluated the impact of the CD4/CD8 ratio on the risk of Kaposi sarcoma (KS) or non-Hodgkin lymphoma (NHL), still among the most frequent cancers in treated PLWH | ||
| 520 | |a METHODS: PLWH from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) were included if they achieved virological control (viral load ≤ 500 copies/mL) within 9 months following cART and without previous KS/LNH diagnosis. Cox models were used to identify factors associated with KS or NHL risk, in all participants and those with CD4 ≥ 500/mm3 at virological control. We analyzed the CD4/CD8 ratio, CD4 count and CD8 count as time-dependent variables, using spline transformations | ||
| 520 | |a RESULTS: We included 56 708 PLWH, enrolled between 2000 and 2014. At virological control, the median (interquartile range [IQR]) CD4 count, CD8 count, and CD4/CD8 ratio were 414 (296-552)/mm3, 936 (670-1304)/mm3, and 0.43 (0.28-0.65), respectively. Overall, 221 KS and 187 NHL were diagnosed 9 (2-37) and 18 (7-42) months after virological control. Low CD4/CD8 ratios were associated with KS risk (hazard ratio [HR] = 2.02 [95% confidence interval {CI } = 1.23-3.31]) when comparing CD4/CD8 = 0.3 to CD4/CD8 = 1) but not with NHL risk. High CD8 counts were associated with higher NHL risk (HR = 3.14 [95% CI = 1.58-6.22]) when comparing CD8 = 3000/mm3 to CD8 = 1000/mm3). Similar results with increased associations were found in PLWH with CD4 ≥ 500/mm3 at virological control (HR = 3.27 [95% CI = 1.60-6.56] for KS; HR = 5.28 [95% CI = 2.17-12.83] for NHL) | ||
| 520 | |a CONCLUSIONS: Low CD4/CD8 ratios and high CD8 counts despite effective cART were associated with increased KS/NHL risks respectively, especially when CD4 ≥ 500/mm3 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CD4/CD8 ratio | |
| 650 | 4 | |a CD8 T-cells | |
| 650 | 4 | |a Kaposi sarcoma | |
| 650 | 4 | |a efficient cART | |
| 650 | 4 | |a non-Hodgkin lymphoma | |
| 700 | 1 | |a Guiguet, Marguerite |e verfasserin |4 aut | |
| 700 | 1 | |a Weiss, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Winston, Alan |e verfasserin |4 aut | |
| 700 | 1 | |a Miro, Jose M |e verfasserin |4 aut | |
| 700 | 1 | |a Konopnicki, Deborah |e verfasserin |4 aut | |
| 700 | 1 | |a Le Moing, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Bonnet, Fabrice |e verfasserin |4 aut | |
| 700 | 1 | |a Reiss, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Mussini, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Poizot-Martin, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Ninon |e verfasserin |4 aut | |
| 700 | 1 | |a Skoutelis, Athanasios |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Goujard, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Bartmeyer, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Boesecke, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Antinori, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Quiros-Roldan, Eugenia |e verfasserin |4 aut | |
| 700 | 1 | |a Wittkop, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Frederiksen, Casper |e verfasserin |4 aut | |
| 700 | 1 | |a Castagna, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Thurnheer, Maria Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Svedhem, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Jose, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Costagliola, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Mary-Krause, Murielle |e verfasserin |4 aut | |
| 700 | 1 | |a Grabar, Sophie |e verfasserin |4 aut | |
| 700 | 0 | |a (CD4/CD8 ratio and cancer risk) project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord |e verfasserin |4 aut | |
| 700 | 1 | |a Judd, Ali |e investigator |4 oth | |
| 700 | 1 | |a Zangerle, Robert |e investigator |4 oth | |
| 700 | 1 | |a Touloumi, Giota |e investigator |4 oth | |
| 700 | 1 | |a Warszawski, Josiane |e investigator |4 oth | |
| 700 | 1 | |a Meyer, Laurence |e investigator |4 oth | |
| 700 | 1 | |a Dabis, François |e investigator |4 oth | |
| 700 | 1 | |a Krause, Murielle Mary |e investigator |4 oth | |
| 700 | 1 | |a Ghosn, Jade |e investigator |4 oth | |
| 700 | 1 | |a Leport, Catherine |e investigator |4 oth | |
| 700 | 1 | |a Wittkop, Linda |e investigator |4 oth | |
| 700 | 1 | |a Reiss, Peter |e investigator |4 oth | |
| 700 | 1 | |a Wit, Ferdinand |e investigator |4 oth | |
| 700 | 1 | |a Prins, Maria |e investigator |4 oth | |
| 700 | 1 | |a Bucher, Heiner |e investigator |4 oth | |
| 700 | 1 | |a Gibb, Diana |e investigator |4 oth | |
| 700 | 1 | |a Fätkenheuer, Gerd |e investigator |4 oth | |
| 700 | 1 | |a Del Amo, Julia |e investigator |4 oth | |
| 700 | 1 | |a Obel, Niels |e investigator |4 oth | |
| 700 | 1 | |a Thorne, Claire |e investigator |4 oth | |
| 700 | 1 | |a Mocroft, Amanda |e investigator |4 oth | |
| 700 | 1 | |a Kirk, Ole |e investigator |4 oth | |
| 700 | 1 | |a Stephan, Christoph |e investigator |4 oth | |
| 700 | 1 | |a Pérez-Hoyos, Santiago |e investigator |4 oth | |
| 700 | 1 | |a Hamouda, Osamah |e investigator |4 oth | |
| 700 | 1 | |a Bartmeyer, Barbara |e investigator |4 oth | |
| 700 | 1 | |a Chkhartishvili, Nikoloz |e investigator |4 oth | |
| 700 | 1 | |a Noguera-Julian, Antoni |e investigator |4 oth | |
| 700 | 1 | |a Antinori, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Monforte, Antonella d'Arminio |e investigator |4 oth | |
| 700 | 1 | |a Brockmeyer, Norbert |e investigator |4 oth | |
| 700 | 1 | |a Prieto, Luis |e investigator |4 oth | |
| 700 | 1 | |a Conejo, Pablo Rojo |e investigator |4 oth | |
| 700 | 1 | |a Soriano-Arandes, Antoni |e investigator |4 oth | |
| 700 | 1 | |a Battegay, Manuel |e investigator |4 oth | |
| 700 | 1 | |a Kouyos, Roger |e investigator |4 oth | |
| 700 | 1 | |a Mussini, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Casabona, Jordi |e investigator |4 oth | |
| 700 | 1 | |a Miró, Jose M |e investigator |4 oth | |
| 700 | 1 | |a Castagna, Antonella |e investigator |4 oth | |
| 700 | 1 | |a Konopnick, Deborah |e investigator |4 oth | |
| 700 | 1 | |a Goetghebuer, Tessa |e investigator |4 oth | |
| 700 | 1 | |a Sönnerborg, Anders |e investigator |4 oth | |
| 700 | 1 | |a Torti, Carlo |e investigator |4 oth | |
| 700 | 1 | |a Sabin, Caroline |e investigator |4 oth | |
| 700 | 1 | |a Teira, Ramon |e investigator |4 oth | |
| 700 | 1 | |a Garrido, Myriam |e investigator |4 oth | |
| 700 | 1 | |a Haerry, David |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 73(2021), 1 vom: 01. Juli, Seite 50-59 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2021 |g number:1 |g day:01 |g month:07 |g pages:50-59 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciaa1137 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2021 |e 1 |b 01 |c 07 |h 50-59 | ||